Literature DB >> 15814845

The nongenomic actions of aldosterone.

John W Funder1.   

Abstract

Aldosterone has physiological effects to regulate fluid and electrolyte homeostasis across epithelia and proinflammatory effects on a variety of nonepithelial cells in the context of inappropriate salt status. These effects are mediated by mineralocorticoid receptors, members of a large family of nuclear transcription factors, by DNA-directed, RNA-mediated protein synthesis. Rapid effects of aldosterone, insensitive to actinomycin D or cycloheximide and thus clearly nongenomic, have been convincingly documented in a variety of epithelial and nonepithelial tissues. Despite strenuous attempts, isolation of a nonclassical membrane receptor for aldosterone has proven unsuccessful, and rapid nongenomic effects mediated by classical mineralocorticoid receptors are increasingly recognized in the kidney, heart, and vascular wall. The mechanism of rapid nongenomic actions of aldosterone may vary between tissues in terms of pathways; in addition, what remains to be established is the physiological role of aldosterone action via such rapid nongenomic mechanisms and how they might synergize with the longer time course genomic actions of mineralocorticoids.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15814845     DOI: 10.1210/er.2005-0004

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  39 in total

Review 1.  Minireview: aldosterone biosynthesis: electrically gated for our protection.

Authors:  Nick A Guagliardo; Junlan Yao; Changlong Hu; Paula Q Barrett
Journal:  Endocrinology       Date:  2012-06-11       Impact factor: 4.736

2.  Effect of aldosterone and its antagonist on the expression of PAI-1 and TGF-β1 in rat hepatic stellate cells.

Authors:  Shenglan Wang; Zhaojie Zhang; Xinyan Zhu; Huimin Wu; Hengjun Gao; Changqing Yang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

3.  Aldosterone blunts tubuloglomerular feedback by activating macula densa mineralocorticoid receptors.

Authors:  Yiling Fu; John E Hall; Deyin Lu; Lin Lin; R Davis Manning; Liang Cheng; Celso E Gomez-Sanchez; Luis A Juncos; Ruisheng Liu
Journal:  Hypertension       Date:  2012-02-06       Impact factor: 10.190

Review 4.  Hippocampal formation: shedding light on the influence of sex and stress on the brain.

Authors:  Bruce S McEwen; Teresa A Milner
Journal:  Brain Res Rev       Date:  2007-02-28

Review 5.  The role of aldosterone in cardiovascular disease in people with diabetes and hypertension: an update.

Authors:  Guido Lastra-Gonzalez; Camila Manrique-Acevedo; James R Sowers
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

6.  Diverse immunostaining patterns of mineralocorticoid receptor monoclonal antibodies.

Authors:  Celso E Gomez-Sanchez; Mary Warden; Miriam T Gomez-Sanchez; Xu Hou; Elise P Gomez-Sanchez
Journal:  Steroids       Date:  2011-09-10       Impact factor: 2.668

7.  Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR/S6K1 pathway.

Authors:  Adam T Whaley-Connell; Javad Habibi; Ravi Nistala; Vincent G DeMarco; Lakshmi Pulakat; Melvin R Hayden; Tejaswini Joginpally; Carlos M Ferrario; Alan R Parrish; James R Sowers
Journal:  Am J Nephrol       Date:  2011-12-24       Impact factor: 3.754

Review 8.  The ubiquitous mineralocorticoid receptor: clinical implications.

Authors:  Urseline A Hawkins; Elise P Gomez-Sanchez; Clara M Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

Review 9.  Genomic and rapid effects of aldosterone: what we know and do not know thus far.

Authors:  Milla Marques Hermidorff; Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

10.  Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?

Authors:  Iwan C C van der Horst; Adriaan A Voors; Dirk J van Veldhuisen
Journal:  Clin Res Cardiol       Date:  2007-02-15       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.